ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong ...

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and ...

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further ...

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon’s lining. Common symptoms include ...

As DEI battles and funding shifts roil campuses, music programs from UCLA to Juilliard continue to grow. THR ranks the 20 schools shaping the next generation of composers. By Jeff Bond Conservatories ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

YouTube is celebrating 10 years of its YouTube Music app on Thursday with the launch of new features that bring it closer to rival Spotify and others. The app will now include “Taste Match” playlists, ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

AbbVie sees limited tariff impact due to U.S. manufacturing Skyrizi and Rinvoq sales exceed analyst expectations Venclexta to benefit from Trump's "one big beautiful bill" July 31 (Reuters) - AbbVie ...

AbbVie’s ABBV2.10%increase; green up pointing triangle beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill.

AbbVie ABBV reported second-quarter revenue of $15.4 billion (6.6% growth) and adjusted diluted earnings per share of $2.97 (12.1% growth). Management raised full-year revenue guidance to $60.5 ...